This was a good editorial comment and we thank the editors for the appreciation of the positive outcome with mirabegron in patients with the overactive bladder syndrome (OAB). Indeed we are enthusiastic about the efficacy and limited side effects of this first drug of a new pharmacologic class approved by the Food and Drug Administration and available for the treatment of patients with symptoms of OAB. We see mirabegron as a welcome additional therapeutic modality for patients with OAB that does not show sufficient clinical efficacy with other forms of pharmacologic treatment.
展开▼
